权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Peptide Synthesis and Purification Core Facility

肽合成与纯化核心设施

基本信息

批准号：
7466200
负责人：
G M ANANTHARAMAIAH
金额：
$ 11.95万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
起止时间：
2008-05-01 至 2013-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7466200
关键词：
Alzheimer&apos s Disease Amino Acids Apolipoproteins A Atherosclerosis Biology Blood Vessels Core Facility Cost Savings Country Cultured Cells Diabetes Mellitus Disease Drug or chemical Tissue Distribution Fatty Acids Glass Goals High Density Lipoproteins High Pressure Liquid Chromatography Home environment Inflammatory Label Laboratories Length Liquid Chromatography Literature Methods Numbers Operative Surgical Procedures Paper Peptide Synthesis Peptides Phase Philadelphia Plant Resins Procedures Process Proteins Publications Publishing Radiolabeled Reaction Recombinant Proteins Research Research Design Research Personnel Role Site Staging Structure System Technology Time United States National Institutes of Health Universities Washington Wisconsin base day fast protein liquid chromatography improved in vivo instrumentation mimetics peptide analog pressure programs radiotracer silochrome size synthetic peptide

项目摘要

A. Administration. This facility will provide synthetic peptides for studies described mainly in projects 2, 3 and 4. This core is directed by Dr. Anantharamaiah, and Dr. Palgunachari will assist in the day-to-day operation of this facility. This core facility has been highly productive and has supported this program project extensively and therefore, an important component of this program project application. B. Instrumentation. The facility possesses three Protein Technology automatic peptide synthesizers and one Advanced ChemTech (ACT 90) peptide synthesizer. While the Protein Technology peptide synthesizers can provide small amounts of the peptides (in mg quantities) in a shorter duration due to the addition of ten times excess of incoming amino acids on to the amino acid-resin, the ACT can provide 10g quantities of peptides but the process is slow since one amino acid is added per day after the completion of reaction is ascertained at each stage of the synthesis. Since the starting resin used in ACT 90 is more, we avoid adding more than the required excess of amino acid derivatives at each stage in order to save costs on amino acid derivatives. For the purification of peptides the core facility possesses three Beckman analytical HPLC and two preparative HPLC units (Beckman and Varian). In addition to this, the core facility utilizes BioRad FPLC systems that are connected to Michel Muller Medium Pressure Liquid Chromatography (MPLC) glass columns. These columns are of various sizes with the smallest (analytical) containing 12g of the stationary phase (C-4 or C-18 silica gel) and the biggest column containing 800g of "home made" reverse phase stationary phase (C-4 and C-18 Reversed Phase silica gels). We routinely alkylate Silica Gel with various chain-lengths of fatty acids. At a time we produce 2 kg to 4kg of the stationary phase for home made columns. This provides a higher capacity to purify large quantities of synthetic peptides. These columns are also used to purify recombinant proteins. A typical procedure will be described in the Methods Section.

答:管理。该设施将提供合成肽的研究主要描述在